167 related articles for article (PubMed ID: 38725630)
1. Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review.
Wang L; Huang Y; Sun X
Front Oncol; 2024; 14():1362160. PubMed ID: 38725630
[TBL] [Abstract][Full Text] [Related]
2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.
Dai G; He L; Yan Q; Li Y; Huang Y; Li B; Wang G
Front Oncol; 2023; 13():1167516. PubMed ID: 37456237
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Qian X; Wang Y; Liu F; Yuan Y; Fang C; Zhang X; Yuan S; Chen R; Yu B; Wang T; Yin Y; Li Y
Front Immunol; 2022; 13():956982. PubMed ID: 36389780
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review.
Wen Y; Dong Y; Yi L; Yang G; Xiao M; Li Q; Zhao C; Ye D; Yao Y
Front Oncol; 2023; 13():1241475. PubMed ID: 37920159
[TBL] [Abstract][Full Text] [Related]
8. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.
Cao JZ; Wu W; Pan JF; Wang HW; Jiang JH; Ma Q
Front Oncol; 2021; 11():643413. PubMed ID: 34109111
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
Sun C; Ma X; Jiang L; Zhu X
Anticancer Drugs; 2024 Apr; 35(4):358-361. PubMed ID: 38385998
[TBL] [Abstract][Full Text] [Related]
13. Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB
Huang N; Qu T; Zhang C; Li J
Front Oncol; 2024; 14():1269148. PubMed ID: 38414747
[TBL] [Abstract][Full Text] [Related]
14. Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation.
Zhu S; Yu C; Wang C; Ding G; Cheng S
Front Oncol; 2022; 12():969106. PubMed ID: 36330483
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
Chen X; Li W; Wu X; Zhao F; Wang D; Wu H; Gu Y; Li X; Qian X; Hu J; Li C; Xia Y; Rao J; Dai X; Shao Q; Tang J; Li X; Shu Y
Front Oncol; 2022; 12():909035. PubMed ID: 35712486
[TBL] [Abstract][Full Text] [Related]
16. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
Fu L; Chen P; Wang S; Liu W; Chen Z; Chen H; Fu Z
Anticancer Drugs; 2022 Jan; 33(1):e741-e746. PubMed ID: 34338239
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review.
Liu Z; Yu M; Zhao F; Zhu C
Front Oncol; 2023; 13():976415. PubMed ID: 37007162
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
[TBL] [Abstract][Full Text] [Related]
20. Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.
Wang M; Gong Y; Cheng Y; Yang L; Wang W; Lei X
Oncol Lett; 2022 Oct; 24(4):343. PubMed ID: 36072009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
